InMed (INM) - Gunggung dhuwit awis saben saham

InMed - logo grafis emiten INM

Developing synthetic cannabinoids via the Integram platform to combat skin and eye pathologies requires colossal investment. An analysis of cash per share demonstrates a steady decline in liquidity due to high R&D expenses, while the metric remains around 2.05. However, the unique biosynthesis of pure substances provides InMed Pharmaceuticals (INM) with significant pricing power due to inelastic patient demand.

InMed Pharmaceuticals Inc (INM): Dana dhuwit saben saham saka 04.07.2022 nganti 09.11.2026

Rincian metrik komprehensif lan analitis inmedpharma.com (INM)

- rega saham lan target rega konsensus:
- indikator anane dhuwit lan arus kas:
Ringkesan analisis perusahaan:INM InMed Pharma
Produk mawa merek InMed Pharmaceuticals

This metric assesses the level of net liquidity available per common share to determine the real value of assets. Analyzing current cash per share helps identify the risk of underinvesting in business development. The metric is calculated by dividing total cash holdings by the number of issued securities. For InMed Pharmaceuticals (INM), this reserve is critical during the pre-commercial sales period, as these funds provide financing for clinical trials of biosynthetic dermatology drugs.